Changeflow GovPing Pharma & Drug Safety Human Anti-Human CD22 CAR Patent Application EP...
Routine Notice Added Final

Human Anti-Human CD22 CAR Patent Application EP4130040A1

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Peptides (C07K)
Published March 11th, 2026
Detected March 26th, 2026
Email

Summary

The European Patent Office has published patent application EP4130040A1 concerning a fully human anti-human CD22 chimeric antigen receptor and its application, filed by Nanjing Iaso Biotechnology Co., Ltd. The publication date is March 11, 2026.

What changed

European patent application EP4130040A1, titled 'FULLY HUMAN ANTI-HUMAN CD22 CHIMERIC ANTIGEN RECEPTOR AND APPLICATION THEREOF', has been published by the EPO. The application was filed by Nanjing Iaso Biotechnology Co., Ltd. and lists HU, Guang et al. as inventors. The publication date is March 11, 2026.

This publication represents a new patent application filing and does not impose immediate compliance obligations. However, it is relevant for companies operating in the biotechnology and pharmaceutical sectors, particularly those involved in CAR T-cell therapy development, as it may impact intellectual property landscapes and future research or commercialization efforts. Companies should monitor the prosecution of this patent application.

Source document (simplified)

← EPO Patent Bulletin

FULLY HUMAN ANTI-HUMAN CD22 CHIMERIC ANTIGEN RECEPTOR AND APPLICATION THEREOF

Publication EP4130040A1 Kind: A1 Mar 11, 2026

Applicants

Nanjing Iaso Biotechnology Co., Ltd.

Inventors

HU, Guang, YANG, Yongkun, NIU, Panpan, MENG, Guangrong, CHENG, Wei, MO, Jialu

IPC Classifications

C07K 16/28 20060101AFI20240322BHEP C12N 15/13 20060101ALI20240322BHEP C07K 19/00 20060101ALI20240322BHEP A61K 39/395 20060101ALI20240322BHEP C12N 15/62 20060101ALI20240322BHEP C12N 5/10 20060101ALI20240322BHEP A61P 35/00 20060101ALI20240322BHEP A61K 39/00 20060101ALI20240322BHEP C07K 14/725 20060101ALI20240322BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
EPO
Published
March 11th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP4130040A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Drug Development CAR T-cell Therapy
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Biotechnology Intellectual Property

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Peptides (C07K) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.